HOME >> BIOLOGY >> NEWS
Discovery Of A Molecule That Controls Bile Acids May Lead To New Cholesterol Drugs

DALLAS - May 21, 1999 - The discovery that a nuclear receptor controls the production of bile acids and works within a pathway that speeds up destruction of cholesterol may lead to new cholesterol drugs, UT Southwestern researchers reported in today's issue of Science.

Their finding -- that the receptor FXR (farnesoid orphan receptor) is integral to maintaining the balance of cholesterol and bile acids -- has important implications for developing drugs to control dietary cholesterol in humans, said corresponding author of the study Dr. David Mangelsdorf, associate professor of pharmacology and Howard Hughes Medical Institute (HHMI) investigator.

"Our finding that FXR functions as a bile-acid receptor suggests an expanded model for the regulation of cholesterol homeostasis by nuclear receptors," Mangelsdorf said. He and other researchers previously had shown that accumulation of dietary cholesterol in the liver triggers production of biochemicals called oxysterols. These substances activate liver orphan receptor (LXR) to speed up the breakdown of cholesterol for conversion to bile acids and steroid hormones.

"If we find an antagonist to FXR, then it might increase bile-acid production to control cholesterol," Mangelsdorf said. Both LXR and FXR are members of a family of protein molecules located in the nucleus of cells found in the liver, intestine, kidneys and adrenal glands. Their role in removing cholesterol from the body is important because it prevents arteriosclerosis, which leads to heart attacks.

This study showed that elevated bile acids regulated further production and transport through FXR. This leads Mangelsdorf to believe that FXR is one of the key regulators that controls repression and further synthesis in the liver and increases the production of other proteins that transport bile acids in the intestine.

"People can't live without bile acids as a way to rid the body of cholesterol, so o
'"/>

Contact: Susan Steeves
susan.steeves@email.swmed.edu
214-648-3404
UT Southwestern Medical Center
21-May-1999


Page: 1 2

Related biology news :

1. Discovery of new shrimp species adds to unique family
2. Discovery of tiny microbes in ancient Greenland glacier may define limits for life on Earth
3. Discovery in parasite movement may offer insights into malaria
4. Scientists find second way to kill cancer cells: Discovery opens possibilities for new therapies
5. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2004
6. Discovery helps explain how cells package DNA
7. Discovery offers clues to origin of life
8. Discovery could improve anemia treatment in patients
9. Discovery could lead to better treatment for cryptosporidum infections
10. Discovery of brain disorder gene paves way for genetic test
11. Discovery may be first plant cell surface molecule that halts cell proliferation

Post Your Comments:
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
(Date:3/5/2015)... March 05, 2015 e2b teknologies ... Partner located in Northeast Ohio, today announced a leading ... to support its upgrade to the latest version of ... independent group practice of its kind in the region, ... volume of transactions, so efficiency and data accessibility are ...
(Date:3/4/2015)... 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the: , 3.75% Convertible Senior Notes due May ... stock per $1,000 principal amount or approximately $5.72 per share, ... the note is adjusted in connection with the regular quarterly ... all stockholders who own shares of PDL on March 5, 2015, ...
(Date:3/4/2015)...  Brooklyn residents now have a new place to ... injuries. Nunzio Saulle , M.D., a board-certified physiatrist, ... NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 2015. Health Plus Management, LLC is managing the day-to-day ... Flatbush Avenue. This new PM&R practice will treat patients ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biologics and Biosimilars Industry Report 2015" ... The Global Biologics and Biosimilars Industry Report ... the current state of the biologics and biosimilars ... overview of the industry including definitions, classifications, applications ...
Breaking Biology Technology:Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biologics and Biosimilars Industry Report 2015-2020 2
Cached News: